Member- Aug 14, 2013
- 2,457
- Tinnitus Since
- Resolved since 2016
- Cause of Tinnitus
- Unknown (medication, head injury)
This will be the "official" TinnitusTalk kick-off thread for AM-102.
After a fair bit of research via financial sources I am able to at least shed a little light on what the so-far undisclosed compound of Auris Medical's secret AM-102 tinnitus "weapon" might be. The addition of two new drugs to the overall pipeline of Auris Medical created some interest, this past Summer.
Source: http://www.aurismedical.com/product-candidates/pipeline
My initial own - incorrect - intrepretation was that this new compound to combat tinnitus would not be an otologic application but instead most likely an orally delivered medication such as a new potassium channel modulator (ie. a direct competitor to AUT00063). This idea became increasingly likely when I recently learned that a new version of a Kv7.2/3 potassium modulator will hopefully soon head into clinical trials (something which remains unpublished at the moment). The background for this (incorrect) assumption of mine was the timing of events - something I have commented on in this thread earlier today:
https://www.tinnitustalk.com/threads/retigabine-trobalt-potiga-—-general-discussion.5074/page-105#post-81478
But it would now definitely seem that AM-102 is not a new novel potassium modulator, but yet another intratympanic delivered compound (the nature of which remains undisclosed - but read on!). What is also surprising - to me - is that this compound has actually been under development since at least 2010 (and possibly earlier). Why it has not been disclosed - or even mentioned in the official pipeline - until this Summer may have to do with the fact that Auris Medical AG is now a publicly listed company (EARS) and is therefore required to present more information in public; it may also simply be because the pipeline is progressing to a point where a "break-through" is imminent (ie. an upcoming phase-I trial).
Here is the financial information that I have found:
It would therefore seem that AM-102 is not one, but two(?) compounds, and that XIGEN is the supplier (a fact that is not new). And indeed it would seem that this is another intratympanicly delivered application (which is a surprise to me because AM-101 already exists...).
Now people of this forum will hopefully understand why a background in finance is what counts in life...!
(Disclaimer: please be aware that the information I have found may not be 100% correct, but I have done my best to ensure the accuracy of the data and my own comments above).
After a fair bit of research via financial sources I am able to at least shed a little light on what the so-far undisclosed compound of Auris Medical's secret AM-102 tinnitus "weapon" might be. The addition of two new drugs to the overall pipeline of Auris Medical created some interest, this past Summer.
Source: http://www.aurismedical.com/product-candidates/pipeline
My initial own - incorrect - intrepretation was that this new compound to combat tinnitus would not be an otologic application but instead most likely an orally delivered medication such as a new potassium channel modulator (ie. a direct competitor to AUT00063). This idea became increasingly likely when I recently learned that a new version of a Kv7.2/3 potassium modulator will hopefully soon head into clinical trials (something which remains unpublished at the moment). The background for this (incorrect) assumption of mine was the timing of events - something I have commented on in this thread earlier today:
https://www.tinnitustalk.com/threads/retigabine-trobalt-potiga-—-general-discussion.5074/page-105#post-81478
But it would now definitely seem that AM-102 is not a new novel potassium modulator, but yet another intratympanic delivered compound (the nature of which remains undisclosed - but read on!). What is also surprising - to me - is that this compound has actually been under development since at least 2010 (and possibly earlier). Why it has not been disclosed - or even mentioned in the official pipeline - until this Summer may have to do with the fact that Auris Medical AG is now a publicly listed company (EARS) and is therefore required to present more information in public; it may also simply be because the pipeline is progressing to a point where a "break-through" is imminent (ie. an upcoming phase-I trial).
Here is the financial information that I have found:
It would therefore seem that AM-102 is not one, but two(?) compounds, and that XIGEN is the supplier (a fact that is not new). And indeed it would seem that this is another intratympanicly delivered application (which is a surprise to me because AM-101 already exists...).
Now people of this forum will hopefully understand why a background in finance is what counts in life...!
(Disclaimer: please be aware that the information I have found may not be 100% correct, but I have done my best to ensure the accuracy of the data and my own comments above).
Founder
